Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Bcl-6

Bcl-6 (B-cell lymphoma 6) is a zinc finger transcription factor that acts as a key regulator of B cell development and immune responses. It functions primarily as a transcriptional repressor, controlling genes involved in cell proliferation, apoptosis, and differentiation. BCL6 is essential for the formation of germinal centers during humoral immunity, where it regulates B cell maturation and antibody production. Dysregulation of BCL6 is associated with lymphomas, particularly diffuse large B-cell lymphoma (DLBCL), where it promotes cell survival and proliferation. Due to its critical role in immunity and cancer, BCL6 is a potential therapeutic target in hematological malignancies.

ARV-393
T843162851885-95-3
ARV-393 is a PROTAC degrader targeting BCL6 with the advantage of being highly potent and orally available.ARV-393 recruits BCL6 and E3 ligase cerebellum to rapidly degrade BCL6 through the cell's natural ubiquitin proteasome system for the treatment of diffuse large b-cell lymphoma (DLBCL) and non-Hodgkin's lymphoma (NHL).
  • $223
In Stock
Size
QTY
Glycochenodeoxycholic Acid
T4588640-79-9
Glycochenodeoxycholic Acid (Lithocholylglycine) is a glycine conjugate of lithocholic acid, a bile acid. It is increased in livers of mice that are fed diets supplemented with ursadeoxycholic acid. Glycolithocholic acid levels are decreased in lean mice treated with obestatin. Serum glycolithocholic acid levels increase with age in children.
  • $30
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
BI-3802
T54082166387-65-9
BI-3802, a highly potent BCL6 degrader, targets and inhibits the Bric-à-brac (BTB) domain of BCL6, exhibiting an IC50 value of ≤3 nM. It induces polymerization of BCL6 and facilitates its degradation in a manner dependent on the E3 ligase SIAH1, demonstrating notable antitumor activity[1][2].
  • $127
In Stock
Size
QTY
ARV-393 HCl
T84316L In house
ARV-393 HCl is an orally active and potent PROTAC targeting BCL6 with antitumor activity for the study of non-Hodgkin's lymphoma.
  • $226
In Stock
Size
QTY
BCL6-IN-3
T104872253878-44-1
BCL6-IN-3 is a potent BCL6 inhibitor with GI50 of 70 nM in SU-DHL4 cells. BCL6-in-3 regulates cell activation, differentiation, DNA damage and apoptosis, and has antitumor activity.
  • $117
In Stock
Size
QTY
Glycochenodeoxycholic acid sodium salt
T525916564-43-5
Glycochenodeoxycholic acid sodium salt is a bile salt formed in the liver from deoxycholic acid and glycine that induces apoptosis in hepatocytes. It acts as a detergent, dissolves fats for absorption, and is itself absorbed.
  • $41
In Stock
Size
QTY
FX1
T40891426138-42-2
FX1 is an effective and selective BCL6 inhibitor (IC50: 35 μM).
  • $34
In Stock
Size
QTY
TargetMol | Citations Cited
BCL6-IN-6
T600082408882-54-0
BCL6-IN-6 is an inhibitor of Bcl-6 and can be used in studies about diffuse large B-cell lymphoma. BCL6-IN-6 blocks the interaction of Bcl-6 with its corepressors and dose-dependently reactivates Bcl-6 target genes.
  • $41
In Stock
Size
QTY
CID5721353
T3940301356-95-6
CID5721353 (BCL6 inhibitor) is a B-Cell Lymphoma 6 Inhibitor (BCL6 inhibitor) that disrupts BCL6/corepressor complexes in vitro and in vivo, and was shown to bind the critical site within the BTB groove.
  • $30
In Stock
Size
QTY
TL4-12
T262801620820-12-3
TL4-12 is a specific MAP4K2/GCK inhibitor that inhibits IKZF1 and BCL-6.TL4-12 inhibits MM cell proliferation and induces apoptosis, and can be used in the study of multiple myeloma (MM).
  • $92
In Stock
Size
QTY
BCL6-IN-7
T87312097518-46-0
BCL6-IN-7 (BCL6 inhibitor-7) is a BCL6 co-repressor interaction inhibitor with potential anticancer activity. It can be used for studying lymphomas.
  • $59
In Stock
Size
QTY
BI-3812
T145612166387-64-8
BI-3812 is an inhibitor of BCL6. Which inhibiting the BTB domain of BCL6 (IC50: 3 nM). BI-3812 also has antitumor activity.
  • $112
In Stock
Size
QTY
OICR11029
T2050402374711-65-4
OICR11029 is a potent probe for Bcl-6.
  • Inquiry Price
Size
QTY
EB-TCIP
T206944
EB-TCIP (BAK-04-212) is a bivalent molecule composed of AP1867 and BI-3812. It facilitates the reversible formation of a ternary complex between FKBPF36V and BCL6BTB, thereby recruiting FKBP12F36V-tagged EWS/FLI1 to DNA sites bound by the transcriptional regulator BCL6, rapidly inducing expression of BCL6 target genes such as SOCS2 and CXCL11. EWS/FLI1 is a fusion transcription factor found in Ewing sarcoma. EB-TCIP is applicable for studying transcriptional dysregulation in cancer.
  • Inquiry Price
Size
QTY
MNN-02-155
T2068053067681-22-2
MNN-02-155 is a bivalent molecular glue that can simultaneously interact with both p300/CBP and BCL6. It effectively induces the activation of BCL6-targeted reporter genes and promotes cell death. This compound is used in the research of diffuse large B-cell lymphoma (DLBCL).
  • Inquiry Price
Size
QTY
CDK-TCIP2
T201211
DK-TCIP2 is an anticancer agent formed by linking the CDK9 inhibitor SNS-032 and the BCL6 inhibitor BI-3812. This compound exhibits anticancer activity both in vivo and in vitro, making it suitable for research in lymphoma.
  • Inquiry Price
Size
QTY
BMS-986458
T2063533005272-36-3
BMS-986458 is a highly selective, orally active BCL6 PROTAC degrader. It specifically targets cereblon (CRBN) and the BCL6 N-terminal BTB domain to catalyze proximity-induced BCL6 degradation. BMS-986458 is applicable for research in B-cell non-Hodgkin lymphoma.
  • Inquiry Price
10-14 weeks
Size
QTY
JWZ-7-7-Neg1
T887713008612-30-1
JWZ-7-7-Neg1, a neighboring transcription chemical inducer (TCIP), serves as a negative control. It exhibits reduced binding capabilities to BRD4 or BCL6 compared to JWZ-7-7, resulting in lower cytotoxicity towards DLBCL cells.
  • Inquiry Price
Size
QTY
SMRT peptide
TP2772857026-08-5
SMRT peptide, one of the corepressor factors interacting with the BCL6 BTB domain, binds to the BTB domain of BCL6 to enhance its transcriptional repression function. Additionally, SMRT peptide is utilized for studying protein-protein interactions.
  • Inquiry Price
Size
QTY
CCT374705
T781772640647-90-9
CCT374705, an orally active BCL6 inhibitor, exhibits potent antiproliferative effects in vitro and effectively inhibits tumor growth in a lymphoma xenograft mouse model [1].
  • Inquiry Price
8-10 weeks
Size
QTY
TCIP3
T2068503067681-36-8
TCIP3 is a bivalent molecular glue (molecular glue) that can simultaneously bind to both p300/CBP and BCL6. It redirects p300 and CBP to activate programmed cell death genes, which are typically repressed by the oncogenic driver BCL6. TCIP3 is useful for studying diffuse large B-cell lymphoma (DLBCL) and is not toxic to untransformed tonsil lymphocytes or fibroblasts.
  • Inquiry Price
Size
QTY
BCL6 PROTAC 1
T738692257479-54-0
BCL6 PROTAC 1 is a selective B-cell lymphoma 6 (BCL6) proteolysis targeting chimera (PROTAC) that inhibits the BCL6 cell reporter with an IC50 of 8.8 µM and significantly degrades BCL6 in diffuse large B-cell lymphoma (DLBCL) cell lines, making it valuable for tumor-related research [1].
  • Inquiry Price
Size
QTY